Page 159 - Q26 -
P. 159
¥ÿ≈æ“À
çEye on the Ball: Medicine Regulation -Not IP Enforcement -Can Best Deliver
Quality Medicines. -OXFAM International, 2011. https://www.oxfam.org/
en/research/eye-ball.
Frontières, Médecins Sans.†Neither Expeditious, Nor a Solution: The WTO 30
August Decision Is Unworkable. An illustration through Canadaûs Jean
Chrétien Pledge to Africa, 2006.
çHIV Drug Patent Landscape in China.é Initiative for Medicines, Access and
Knowledge (I-MAK), 2010.
Kapczynski, Amy. çHarmonization and Its Discontents: A Case Study of TRIPS
Implementation in Indiaûs Pharmaceutical Sector.é†California Law
Review†97, no. 9 (2009): 1630.
Kessomboon, N. çImpact on Access to Medicines from TRIPS-Plus: a Case
Study of Thai-US FTA.é†Southeast Asian J Trop Med Public Health†41
(2010): 667.
Ketchell, Misha. çThe Problem Drug Patents Pose for Developing Countries.é
The Conversation, 2005. http://theconversation.com/explainer-the-
problem-drug-patents-pose-for-developing-countries-45667.
Limpananont, Jiraporn et al. çPharmaceutical Product Patent Database
Development Project.é Social Pharmacy Research Unit, Faculty of
Pharmaceutical Sciences, Chulalongkorn University (2004).
Noveck, Beth Simone. çùPeer to Patentû: Collective Intelligence, Open Review,
and Patent Reform.é†Harvard Journal of Law & Technology†20 (2006):
123-24.
148 ‡≈à¡∑’Ë Ò ªï∑’Ë ˆ˜
